ErbB2 tyrosine kinase inhibitors (TKI) block tyrosine autophosphorylation and activation of the full-length transmembrane ErbB2 receptor (p185 TKIs. Furthermore, the expression of p95L was increased in ErbB2+ breast cancer models of acquired therapeutic resistance to lapatinib that mimic the clinical setting.
, is deregulated in 25% of all breast cancers, where it predicts for a poor clinical outcome (1) . ErbB2 activation requires autophosphorylation of tyrosine (Y) residues within the cytoplasmic domain of the receptor e.g. Y1248 (2) . These phosphotyrosine residues serve as docking sites for adaptor proteins that link ErbB2 to downstream mitogen activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) signaling networks that promote the growth and survival of breast cancer cells (2) (3) (4) (5) (6) . In addition to p185 ErbB2 , truncated forms of ErbB2 lacking all or most of the N-terminus extracellular domain (ECD) exist in ErbB2+ breast cancer cell lines and clinical tumors (7-10). The most extensively studied truncated forms retain the transmembrane region and are expressed at the cell surface.
Historically referred to as "p95", truncated forms of ErbB2 expressed at the cell surface form heterodimers with other ErbB receptors (11), and interact with the p85 subunit of PI3K (12), thereby activating downstream signal transduction cascades in a manner similar to p185
ErbB2
. The generation of p95 has been shown to be dependent upon metalloproteinase activity (7). P95 positive breast cancers exhibit an aggressive clinical phenotype characterized by an increased incidence of lymph node involvement at the time of initial diagnosis (13, 14) . and are more resistant to trastuzumab since they lack lapatinib has been limited by the development of acquired therapeutic resistance (20, 21).
To address this problem, we generated clinically relevant models of acquired resistance to lapatinib using human ErbB2+ breast cancer cell lines (22, 23).
We now show that treatment with ErbB2 TKIs increased the expression of a tyrosine phosphorylated, truncated form of ErbB2 that was expressed in the nuclei of ErbB2+ breast cancer cells, which will herein be referred to as p95L (lapatinib-induced p95). In contrast to truncated forms of ErbB2 expressed at the cell surface, the phosphorylation of p95L, and similar truncated forms that were also expressed in tumor cell nuclei, was resistant to ErbB2 TKI. The data supporting the activation and nuclear localization of p95L in response to ErbB2 TKI, and the role of nuclear, truncated forms of ErbB2 in the development of therapeutic resistance to ErbB2 TKIs, will be discussed.
Details of cell fractionation, immunoprecipitation, SDS-PAGE, and Western blot analysis were previously described (22). Membranes were probed with specific antibodies recognizing target proteins, and visualized using the Odyssey Infrared Imaging System (LI-COR, Inc., Lincoln, NE). Membranes were incubated with fluorescentlabeled secondary antibody at a 1:10000 dilution with 3% BSA in PBS for 60 min protected from light. After washing in PBS + 0.1% tween-20, the membranes were scanned using an Odyssey imaging system. Human tumor xengrafts, animal treatment, and human tumor biopsies. according to the manufacturer's protocol. Stably transfected cells were selected using G418 (400 μg/ml) and the expression levels of CTF's were confirmed by Western blot analysis.
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Immunofluorescence microscopy
Cells were cultured in 6 well plates with or without the indicated treatments. After washing with PBS, cells were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.2% Triton X-100 for 20 min, and blocked with 2% BSA in PBS at room were incubated with FITC-conjugated swine anti-rabbit or rabbit anti-mouse antibodies followed by counterstaining with 1.5 μg/ml DAPI from Vector Labs (Burlingame, CA).
An Olympus L Fluoview FV1000 was used for all photographs.
Proliferation and apoptosis assay
The proliferation assay was carried out in a 96 well plate format in a final volume of 100 ul/well cell culture medium with the cell proliferation reagent WST-1 from Roche Diagnostics (Mannheim, Germany). Details of the WST-1 profileration and annexin V/ nexin 7-AAD apoptosis assays were previously published (17, 22).
Statistical analysis
Data were expressed as means with standard error bars included. Student's t-test was used to determine statistical significance between 2 groups. P<0.05 was considered a statistically significant difference. 
Results
ErbB2
TKIs increase the expression of phospho-p95L in tumor cell nuclei. The effects of ErbB2 TKI on ErbB2 tyrosine phosphorylation were determined in BT474 cells, a human ErbB2+ breast cancer cell line, using immunofluorescence microscopy (IF). Total ErbB2 protein and phosphotyrosine expression were determined using an ErbB2 specific antibody and a phosphotyrosine (p-tyr) antibody, respectively. ErbB2 and p-tyr signals were visualized using a secondary FITC-conjugated antibody (green). Total ErbB2 expression was unchanged in response to GW2974, an ErbB2 TKI ( Figure 1B ). We next isolated nuclear extracts from BT474 and Au565 cells treated with vehicle alone (controls) or lapatinib. The purity of nuclear extracts was confirmed using Oct 1, IkB, and E-cadherin, which represent nuclear, cytoplasmic, and cell membrane proteins, respectively. Steady-state levels of total p95L protein increased in lapatinibtreated cells without an appreciable change in p185 In Figure 1E , total ErbB2 protein was immunoprecipitated (IP) from nuclear extracts isolated from Au565 cells treated with vehicle alone (control) or GW2974.
Steady-state levels of total (green) and phosphorylated (red) p185 Treatment with lactacystin alone, at the same concentration that blocked induction of p95L, had relatively little antitumor activity in Au565 cells ( Figure 4B ). However, there was enhanced antitumor activity when lactacystin was combined with a sub-lethal concentration of lapatinib (0.1 μM) that was otherwise sufficient to induce p95L.
Expression of truncated ErbB2 reduces the antitumor activity of lapatinib.
To determine the impact of nuclear, truncated forms of ErbB2 on the antitumor activity of lapatinib, we expressed c-676 in BT474 cells ( Figure 5A ). We chose c-676 because of its similarities to p95L e.g. molecular weight, nuclear localization, resistant to ErbB2 TKI.
Using an ErbB2 phosphotyrosine specific antibody in Western blot analysis, we found that lapatinib increased steady-state p95L phosphoprotein levels in cells transfected with Whereas some nuclear truncated forms of ErbB2 are generated through alternate initiation of translation (8), p95L appears to be mediated by the activation of the proteasome, as proteasome inhibitors block its induction ( Figure 4A ). As summarized in 
